Solventum Q2 2026 Earnings: 9.5% Organic Growth Supports Higher Guidance

Solventum (NYSE: SOLV) reported Q2 2026 sales of $2.209 billion, up 2.2% from $2.161 billion, while GAAP diluted EPS increased to $0.53 from $0.51. Organic sales grew 9.5% and adjusted diluted EPS rose 50.9% to $2.55, but legal, separation and restructuring costs caused GAAP operating margin to contract.

Key financial results

Reported sales growth understated the performance of the continuing portfolio because Solventum sold its Purification and Filtration business in September 2025. Divestitures and acquisitions reduced total-company growth by a net 8.3 percentage points, while currency added 1.0 percentage point. Organic growth was driven primarily by volume, product mix and advance orders ahead of ERP cutovers.

Profitability diverged sharply by accounting basis. Gross margin improved, but a 20.1% increase in SG&A expenses—primarily from separation activities and net legal costs—pushed GAAP operating income lower. Adjusted results excluded these and other specified items.

Adjusted gross margin, adjusted operating income, adjusted EPS and free cash flow are non-GAAP measures.

Business and segment performance

All three reportable segments generated organic growth and expanded operating margins. MedSurg remained the largest segment, while Health Information Systems produced the highest segment margin.

Within MedSurg, Advanced Wound Care sales increased 14.9% to $537 million, including organic growth of 7.1%. Infection Prevention and Surgical Solutions grew 11.3% to $836 million, with organic growth of 10.1%. The difference between Advanced Wound Care’s reported and organic growth partly reflected the December 2025 acquisition of Acera.

Solventum also announced its intent to separate Health Information Systems. The proposed transaction is intended to leave Solventum more focused on its MedTech operations while allowing the software business to pursue separate growth and innovation priorities. Health Information Systems represented $354 million of quarterly sales and generated $145 million of segment operating income.

Timing benefits lifted adjusted performance while legal and separation costs weighed on GAAP margin

Some of the quarter’s organic growth and margin expansion came from timing-related factors. Advance orders placed before ERP cutovers contributed to sales, while the ERP timing benefit and an IEEPA tariff refund supported adjusted operating margin. These factors make the durability of the quarter’s 9.5% organic growth and 28.4% adjusted operating margin important to monitor.

At the same time, GAAP operating margin fell despite the higher gross margin. The reconciliation from $181 million of GAAP operating income to $627 million of adjusted operating income included $157 million of litigation-related costs, $145 million of 3M spin-off and separation costs, $90 million of amortization and $42 million of restructuring costs, among other adjustments. This explains why adjusted EPS rose much faster than GAAP EPS.

Profitability, cash flow and the balance sheet

Lower interest expense helped offset the decline in GAAP operating income. Net interest expense fell to $64 million from $103 million, allowing net income to rise slightly even though operating income declined.

Quarterly operating cash flow increased to $227 million and free cash flow reached $144 million. Management attributed the performance partly to the timing of tax payments and insurance proceeds, meaning the quarter’s cash generation was not driven solely by operating earnings.

The first-half figures remained weaker than the quarterly result. For the six months ended June 30, operating cash flow was $38 million and free cash flow was negative $129 million, compared with $198 million and negative $21 million, respectively, a year earlier. Accounts receivable used $286 million of cash during the first half.

Cash and equivalents declined to $403 million from $878 million at the end of 2025. Solventum also spent $355 million on treasury stock during the first half, while current debt stood at $506 million and long-term debt was $4.573 billion as of June 30.

Full-year 2026 guidance

Solventum raised all three of its principal full-year non-GAAP guidance measures. The higher ranges indicate increased confidence in organic growth, adjusted earnings and cash generation, although ERP timing and SKU exits remain relevant to the sales outlook.

Excluding an estimated 100-basis-point impact from SKU exits, organic growth is expected to be 3.5% to 4.0%. Given first-half free cash flow of negative $129 million, the updated full-year range implies approximately $329 million to $429 million of free cash flow in the second half.

Risks investors should monitor

• ERP-related order timing: Advance purchases benefited Q2 organic growth and could create uneven sales patterns in subsequent quarters.
• Margin normalization: The IEEPA tariff refund and ERP timing benefit contributed to margin expansion, so adjusted profitability may differ when those benefits are absent.
• Legal and separation expenses: Litigation, restructuring and separation activities produced a large gap between GAAP and adjusted results. The planned Health Information Systems separation introduces additional execution and cost considerations.
• Cash conversion: Q2 cash flow benefited from tax-payment timing and insurance proceeds, while first-half free cash flow remained negative. Reaching the updated annual target requires substantially stronger second-half cash generation.
• Portfolio and SKU effects: The Purification and Filtration divestiture continues to weigh on reported comparisons, while planned SKU exits are expected to reduce full-year organic growth by about 100 basis points.

Summary

Solventum’s Q2 2026 results combined broad organic growth and higher adjusted margins with continued pressure from legal, restructuring and separation costs on GAAP profitability. All reportable segments expanded, and management raised full-year guidance. The main issues for subsequent quarters are how sales and margins perform after ERP and tariff-related benefits normalize, whether cash conversion improves enough to reach the higher free cash flow target, and how the proposed Health Information Systems separation progresses.